Search Results for: prof dr meyer

TV SBT — Interview of Prof. Dr. MC Meyer on Ancestral Knowledge

TV Interview of Prof.

More:
TV SBT -- Interview of Prof. Dr. MC Meyer on Ancestral Knowledge

Posted in Biotechnology | Comments Off on TV SBT — Interview of Prof. Dr. MC Meyer on Ancestral Knowledge

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy…

Pooled data from 137 patients show Orca-T high-precision cell therapy improved overall survival and reduced chronic graft versus host disease compared to standard of care

Orca-T was well-tolerated and resulted in engraftment with regression of marrow fibrosis in patients with myelofibrosis

Manufacturing reliability analysis found vein-to-vein times for all grafts were under 72 hours regardless of donor collection site and transplant center locations

The Precision-T Phase 3 randomized registrational study of Orca-T versus standard of care is now open

MENLO PARK, Calif., April 25, 2022--(BUSINESS WIRE)--Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that positive new data were presented at the 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings in Salt Lake City, Utah.

The new data on Orca Bios lead investigational high-precision cell therapy, Orca-T, include updated results from 137 patients with hematologic malignancies, which continued to show an increase in overall survival rates and a reduction of acute and chronic graft versus host disease (GvHD) compared to standard of care; positive outcomes in a subset of patients with myelofibrosis who received Orca-T; and new analyses demonstrating Orca Bios manufacturing platform is reliable, robust and scalable.

"These data from an expanded group of patients are very encouraging and demonstrate that Orca-T appears to improve survival while reducing GvHD. This could be a compelling option for patients battling serious hematological malignancies who currently face devastating transplant-related risks," said Everett Meyer, M.D., Ph.D., primary investigator. "These results, combined with the reliable and centralized Orca-T manufacturing, could potentially transform treatment options for patients and physicians."

Story continues

Orca Bio presented pooled data from 137 patients in the single-center Phase 2 and multi-center Phase 1b trials of Orca-T with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndromes (MDS), with at least 100 days of follow-up and a median of 341 days. For comparison purposes, an independent CIBMTR-based control arm was identified, consisting of similar patients with hematologic malignancies who received a standard of care allogeneic hematopoietic stem cell transplant ("alloHSCT") over a similar timeframe. Results demonstrated that:

Rates of moderate-to-severe chronic GvHD were low among Orca-T recipients, occurring in only 5% of patients at one year compared to 38% who received a standard alloHSCT.

GvHD-free, relapse-free survival (GRFS) was 71% at one year for Orca-T patients compared to 21% in the CIBMTR-based control arm.

The overall survival for patients who received Orca-T was 90% at one year compared to 68% in the CIBMTR-based control arm.

Additionally, Orca Bio presented findings from a manufacturing reliability analysis of 100 Orca-T products in the Phase 1b trial. All investigational cell therapies were manufactured at Orca Bios cGMP facility in Sacramento, CA, and transplant centers and donor sites were located across the U.S. All products were successfully delivered and infused to patients within 72 hours or less.

"We produce a unique batch of drug for each patient who receives an Orca-T product, and this drug is made up of fresh, living cells that need to be infused on an extremely rapid timeline," said Nate Fernhoff, Ph.D., co-founder and chief scientific officer at Orca Bio. "Reliable and scalable manufacturing have been integral to the development of our therapies since day one. These results not only show that Orca-T continues to reduce GvHD and improve survival rates over time, but that we have maintained the ability to reliably manufacture, deliver and infuse all patients in a timely manner regardless of donor and patient location. This is an important indication of our ability to potentially deliver this therapy urgently and seamlessly to patients in need."

In a separate poster, Orca Bio presented updated data on the treatment impact of Orca-T in 12 patients with myelofibrosis compared to nine patients who received a standard of care alloHSCT. Orca-T recipients had lower incidence of acute and chronic GvHD (33% with Orca-T versus 100% with alloHSCT) and the data suggest Orca-T was well-tolerated. Treatment with Orca-T resulted in engraftment with regression of marrow fibrosis, indicating potential efficacy for the treatment of myelofibrosis.

Based on the favorable results of the Phase 1b and 2 clinical trials, a randomized registrational Phase 3 trial evaluating Orca-T against standard of care alloHSCT, named Precision-T, is now open. More details will be announced in the coming weeks.

Links to the abstracts follow:

Title: Orca-T Demonstrates Encouraging Overall Survival, Gvhd Reduction, and Tolerability in Patients with Hematologic Malignancies Poster Number: 412

Title: Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors Poster Number: 413

Title: Manufacture and Distribution of High-Precision Orca-T Is Reliable, Robust, and Scalable Poster Number: 415

About Orca-TOrca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being studied to treat multiple hematologic malignancies.

About Orca BioOrca Bio is a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life. For more information, visit http://www.orcabio.com and follow Orca Bio on Twitter: @orcabio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005162/en/

Contacts

Corporate CommunicationsKelsey Grossmanmedia@orcabio.com

Investor RelationsJoshua Murrayir@orcabio.com

Excerpt from:
Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy...

Posted in Stem Cell Therapy | Comments Off on Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy…

Olympic Dermatology Welcomes Board-Certified Dermatologist Dr. Hugh Nymeyer as the Newest Member of the Team – ThurstonTalk

The saying goes that beauty is only skin-deep but that doesnt mean caring for our bodys largest organ, the skin, is any less important. Olympic Dermatology (OlyDerm) provides medical and surgical dermatology, skin cancer prevention and care, as well as anti-aging and aesthetic services, to treat nearly every skin condition and keep your skin happy and healthy. They recently welcomed board-certified dermatologist Dr. Hugh Nymeyer to their team. His passion for dermatologic medicine, helping people and impressive education and training makes him a great fit for the OlyDerm family.

Board-certified dermatologists are professionals that have gone through the most rigorous medical education and training. They must complete medical school, a year-long internship, and three years of residency in training in dermatology. This involves an intensive and challenging board exam, which they must pass every 10 years to maintain certification with the American Academy of Dermatology. Board-certified dermatologists must complete a minimum of eight years of education and 12-16,000 hours of required patient care training, making them experts in the field.

Nymeyer completed medical school at University of Texas Southwestern and finished his Internal Medicine Internship and Dermatology Residency at the University of Arkansas for Medical Sciences. His background in science and education lends greatly to his interest in supporting peoples health through dermatology. He loves the challenge and problem-solving that comes with this particular medical specialty.

There are more new therapies in dermatology than any other field of medicine, so we can treat more diseases better and faster than ever before, says Nymeyer. This is not only great news for our patients but also makes the practice of dermatology a rapidly evolving and interesting profession. Working in such a varied and interesting field feeds Nymeyers love of learning while giving him a means to help people live better, healthier lives. I enjoy treating all sorts of patients and conditions, he says. OlyDerm has a practice environment that allows me to practice surgical, medical, and cosmetic medicine all in the same day.

As dermatologists, we are not diagnosing everyone from their blood work, Nymeyer shares. We are listening to patients and closely examining them to determine their needs. From a toddler with a viral rash to a WWII veteran with melanoma, Nymeyer diagnoses and treats many skin conditions including acne, psoriasis, eczema, rosacea, seborrheic dermatitis and skin cancer. Keeping our skin healthy throughout our life requires a regular adherence to gentle skin care, sun avoidance, and not smoking. If we are careful at prevention, then we will avoid many problems later in life.

When working with a board-certified dermatologist, patients are being treated by an experienced and knowledgeable professional. These medical doctors are able to diagnose and treat over 3,000 different skin, hair and nail diseases and conditions. They also understand the interaction between the skin and the rest of the body, and can use this expertise to determine if a skin condition is contributing to underlying health concerns such as high blood pressure, unhealthy cholesterol levels and diabetes. With such advanced knowledge of treatments, board-certified dermatologists are able to effectively choose the best approach for each patient.

The passion Nymeyer has for helping people with their skins wellbeing is very reflective of what OlyDerm founder and board-certified dermatologist Dr. James Brazil has been doing for 30 years, making him a wonderful addition to their practice. Dr. Nymeyer is exceptionally qualified, caring, open and personable, and makes it a priority to really support his patients in achieving greater personal health, says Brazil. With Nymeyer on the team, OlyDerm is able to extend their reach in Thurston County and surrounding communities to care for more people.

Board-certified dermatologists provide a high level of expertise to prevent and treat skin diseases, much needed in every community but not always available. Thats why OlyDerm also sees patients from outlying communities including Shelton, Aberdeen, Chehalis and Centralia. Having Dr. Nymeyer on board enables us to better meet the growing need for quality dermatologic care, says Brazil.

If you are experiencing problems with a new or existing skin condition, contact OlyDerm to schedule your appointment via the Olympic Dermatology website or by calling 360.459.1700. Through their exceptional, caring and qualified staff, providers and board certified dermatologists you can get the support and treatment you need to achieve healthier skin and better overall health today.

Olympic Dermatology424 Lilly Road NE, Olympia360.459.1700

Sponsored

Go here to see the original:
Olympic Dermatology Welcomes Board-Certified Dermatologist Dr. Hugh Nymeyer as the Newest Member of the Team - ThurstonTalk

Posted in Anti-Aging Medicine | Comments Off on Olympic Dermatology Welcomes Board-Certified Dermatologist Dr. Hugh Nymeyer as the Newest Member of the Team – ThurstonTalk

Collaboration aims to shrink the urban-rural divide and address the impact of climate change through student research network – EurekAlert

ST. LOUIS, MO, November 18, 2021 Just as there often exists an urban-rural divide in political and environmental landscapes, urban and rural education systems share the common issue of being under-resourced, especially for science education. As climate change looms over rural agricultural communities, urban heat islands could serve as critical partners for anticipating the future of economically important crops. Kristine Callis Duehl, PhD, the Sally and Derick Driemeyer Director of Education Research and Outreach at the Donald Danforth Plant Science Center and her collaborators at the Jackie Joyner Kersee Foundation and University of Illinois Extension were awarded a three year, $685,000 grant from United States Department of Agriculture to create a synergistic partnership between urban and rural communities in Southern IL to establish a cross-regional curriculum that introduces bioengineering and plant monitoring technology to middle school aged youth in summer programs.

Young people at the Jackie Joyner-Kersee Foundation in East St. Louis, IL and at the Illinois Extension program in Waterloo, IL will monitor corn growth in both regions by using in-demand technology including drones and a microclimate field monitoring system developed by Danforth Center scientist Nadia Shakoor, PhD. By growing and comparing sweet corn, GMO commodity corn, and non-GMO commodity corn, students will see first-hand how bioengineering improves plant health and crop yield. By conducting joint fieldwork and presenting their ideas at a mini-conference, urban and rural youth will establish a collaboration that generates culturally mindful activities as well as authentic data that can help shed light on the impact of climate change on corn harvests. This collaboration will allow rural students to experience FarmBot robotics at work in smaller, urban plots and allow urban students to experience the use of drones used in precision agriculture on larger, rural farms. Ultimately, through this informal authentic research experience, participants will help develop a culturally informed curriculum that can be launched nationwide to establish a network of urban-rural authentic research hubs for non-formal summer programs.

Young people participating in the project will gain an understanding of gene editing and hands-on experience using robotics to plant corn, as well as experience using drone and microclimate monitoring systems to assess corn growth and the microclimate, said Callis-Duehl. It will also provide technological training, and exposure to data analysis to prepare them for the future, as big data analysis has become increasingly critical in agricultural science.

Youth will also gain leadership experience by providing feedback on curriculum so that it evolves and by teaching the youth the partner program how to use the agricultural technology unique to their research area (urban or rural).

Co-Project Directors include Lisa Walsh, Danforth Plant Science Center, Mark Fryer, Jackie Joyner Kersee Foundation and Amy Cope, University of Illinois Extension.

About the Donald Danforth Plant Science CenterFounded in 1998, the Donald Danforth Plant Science Center is a not-for-profit research institute with a mission to improve the human condition through plant science. Research, education, and outreach aim to have impact at the nexus of food security and the environment and position the St. Louis region as a world center for plant science. The Centers work is funded through competitive grants from many sources, including the National Science Foundation, National Institutes of Health, U.S. Department of Energy, U.S. Agency for International Development, U.S. Department of Agriculture and the Bill & Melinda Gates Foundation. Follow us on Twitter at @DanforthCenter.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:
Collaboration aims to shrink the urban-rural divide and address the impact of climate change through student research network - EurekAlert

Posted in BioEngineering | Comments Off on Collaboration aims to shrink the urban-rural divide and address the impact of climate change through student research network – EurekAlert

Exhaled respiratory droplets increase with the onset of COVID-19 infection and with aging and obesity | Harvard John A. Paulson School of Engineering…

Superspreading events have distinguished the COVID-19 pandemic from the early outbreak of the disease. Now, research from Harvard University, Tulane University, MIT and Massachusetts General Hospital finds that a critical factor in these and other transmission events is the propensity of certain individuals to exhale large numbers of small respiratory droplets. The researchers found that age, obesity and COVID-19 infection all correlate with a propensity to breathe out more respiratory droplets.

Understanding the source and variance of respiratory droplet generation may lead to effective approaches to reducing COVID-19 infection and transmission.

The study was published yesterday in the Proceedings of the National Academy of Sciences.

Respiratory droplet generation in the airways varies between people depending on their phenotype, said David Edwards, Associate in Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences and co-author of the study. While our results show that the young and healthy tend to generate far fewer droplets than the older and less healthy, they also show, in combination with the results from nonhuman primates, that any of us, when infected by COVID-19, may be at risk of producing a large number of respiratory droplets. This is an important finding in that the majority of these droplets are smaller than a single micron, meaning they can carry infection deep into our lungs and propagate infection very far in poorly circulated indoor settings.

Using data from an observational study of 194 healthy people, ages 19 to 66, and an experimental study of nonhuman primates with COVID-19, researchers found that exhaled aerosol particles vary greatly between subjects. Those who were older with higher body mass indexes (BMI) and increasing degree of COVID-19 infection had three times the number of exhaled respiratory droplets as others in the study group.

The researchers found that 18 percent of human subjects accounted for 80 percent of the exhaled particles of the group, reflecting a distribution of exhaled aerosol particles analogous to a classical 20:80 super-spreader distribution of airborne infection. The findings suggest that quantitative assessment and control of exhaled aerosol may be critical to slowing the airborne spread of COVID-19 in the absence of an effective and widely disseminated vaccine.

Our nonhuman primate studies suggest that within a few days of infection by SARS-CoV-2 aerosol, exhaled aerosol increases with the rise of viral replication in the airways, reaching a peak within about a week from first infection and then diminishing in magnitude as the infection is cleared to return to baseline within two weeks post infection, said co-author Chad Roy, Professor of Microbiology and Immunology at Tulane School of Medicine and a core scientist at the Tulane National Primate Research Center at Tulane University. We observed these same phenomena with TB-infected nonhuman primates. It seems likely that viral and bacterial infection of the airway weaken airway mucus in similar ways and promote airborne movement of infection with risks to ourselves and those around us.

The authors argue that management of COVID-19 through the restoration of airway lining mucus barrier function, and, monitoring of exhaled aerosol numbers might be important strategies in the control of transmission and infection of COVID-19, and other respiratory infectious diseases, including TB and influenza.

The research was co-authored by Dennis Ausiello, of Massachusetts General Hospital and Harvard Medical School; Jonathan Salzman and Tom Devlin, of Sensory Cloud; Robert Langer, of the Massachusetts Institute of Technology; and Brandon J. Beddingfield, Alyssa C. Fears, Lara A. Doyle-Meyers, Rachel K. Redmann, Stephanie Z. Killeen and Nicholas J. Maness, of Tulane National Primate Research Center .

It was supported in part by National Institute of Allergy and Infectious Disease (Grant # HHSN272201700033I), the National Institutes of Health (Grant # OD01110) and the Bill & Melinda Gates Foundation

Read the original:
Exhaled respiratory droplets increase with the onset of COVID-19 infection and with aging and obesity | Harvard John A. Paulson School of Engineering...

Posted in BioEngineering | Comments Off on Exhaled respiratory droplets increase with the onset of COVID-19 infection and with aging and obesity | Harvard John A. Paulson School of Engineering…

Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of…

NEW BRUNSWICK, N.J., Aug. 20, 2020 /PRNewswire/ --Johnson & Johnson(NYSE: JNJ) today announced Lewis Cantley, Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr. Paul Janssen Award for Biomedical Research for his incisive research revealing the fundamental aspects of metabolism that have profound implications for the understanding, diagnosis and treatment of human diseases such as cancer and diabetes.

"Like all of the past Dr. Paul Janssen Award winners, and indeed like Dr. Janssen himself, Dr. Cantley challenged the status quo, asked provocative questions, and tirelessly followed his curiosity to uncover scientific insights that have led to an expanded understanding of human biology and the development of solutions that can improve people's lives," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. "We are proud to honor the legacy of Dr. Janssen by celebrating today's research pioneers like Dr. Cantley."

Selected by an independent committee of world-renowned scientists, Cantley won for his discovery of phosphoinositide 3 kinase (PI3K), a key enzyme that promotes cell growth and division, and plays a critical role in diseases including cancer to diabetes, as well as rare diseases such as mosaicism. Hejoins 18 scientistswho have received the Dr. Paul Janssen Award since 2004, including threewho went on to win the Nobel Prize.

"I am honored to be named the winner of this year's Paul Janssen Award," said Dr. Cantley, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center and a professor of cancer biology at Weill Cornell Medicine. "I share Dr. Janssen's passion for scientific exploration, and I'm pleased to receive this recognition of the work done in my laboratory."

The Award is part of Johnson & Johnson's Champions of Science initiative to fuel public engagement, support and trust in science.

"The critical role of science in our society has been brought to the forefront by the COVID-19 pandemic," says Seema Kumar, Vice President, Innovation, Global Health and Science Policy Communication, Johnson & Johnson. "Today more than ever, we look to science to provide answers and new solutions to maintain our health and solve complex medical challenges. By sharing the stories of scientists across generations and geographies, from students to those at the pinnacle of their career, like the winners of the Dr. Paul Janssen Award, we hope to engage more people in becoming ardent champions of science."

Dr. Cantley's work will be celebrated during the Champions of Science: Dr. Paul Janssen Award 2020 webcast, open to the public, on Wednesday, September 16, 2020, at 12:30 p.m. ET via Johnson & Johnson's page on LinkedIn. This unique virtual celebration will honor Dr. Cantley, showcase young innovators at the start of their STEM journeys, and engage the public in a conversation about the importance of science in society.

In addition, Dr. Cantley will be honored at a virtual scientific symposium, presented in collaboration with the New York Academy of Sciences, on September 16, 2020, at 9 a.m. ET. The event will feature presentations from leading experts on the biology of cellular metabolism and its role in human health and disease, including Matthew Vander Heiden, M.D., Ph.D. of the Koch Institute for Integrative Cancer Research atMIT, Karen Vousden, Ph.D., of the Francis Crick Institute, and Ulrike Philippar, Ph.D., of Janssen Pharmaceuticals. Click here to register or for additional information.

"Dr. Cantley's discoveries have transformed our understanding of how human cellular metabolism works," said Richard P. Lifton, M.D., Ph.D., President of The Rockefeller University and Dr. Paul Janssen Award committee chair. "The discovery of PI3K has led to better treatment of a range of diseases, bringing hope to countless patients around the world."

"The research of Dr. Cantley has been illustrative in understanding the metabolic properties of malignant cells and in informing more targeted approaches in cancer treatment," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. "Dr. Cantley's contributions have spurred innovations in oncology that have ultimately benefited many patients, and he has inspired many scientists to progress new research strategies."

About Champions of Science Science touches our lives in every imaginable way. From antibiotics and telecommunications, to genomics, precision medicine and 3D printing, science has improved the human condition leading to longer, healthier, happier lives for people all over the world. To continue to advance, science needs champions! As a global healthcare company, The Johnson & Johnson Family of Companies is uniquely positioned to champion the role of science in society. Champions of Science is a multi-faceted public engagement initiative to convene and catalyze champions of science and engage people of all generations and backgrounds to see the unlimited opportunities that science brings. To learn more, visit http://www.jnj.com/champions-of-science

About the Dr. Paul Janssen Award for Biomedical Research Dr. Paul Janssen was one of the 20th century's most gifted and passionate researchers. He helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines.

The Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson in 2004 to honor the memory of Dr. Paul. Since its inception, the Award has recognized 18 outstanding scientists, three of whom have gone on to win the Nobel Prize for the same work. Winners are chosen by an independent selection committee of the world's most renowned scientists. The Award, which includes a $200,000 prize, is presented at ceremonies in September.

Previous winners include:

Learn more about The Dr. Paul Janssen Award at http://www.pauljanssenaward.com

About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. To learn more, visit http://www.jnj.com

SOURCE Johnson & Johnson

http://www.jnj.com

See more here:
Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of...

Posted in Integrative Medicine | Comments Off on Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of…